NuCana (NCNA) Income from Non-Controlling Interests (2017 - 2025)
NuCana (NCNA) reported Income from Non-Controlling Interests of -$360279.7 for Q3 2025, up 93.92% on a YoY basis from -$185784.8 in Q3 2024, and up 98.88% sequentially from -$32.2 million in Q2 2025.
NuCana (NCNA) Income from Non-Controlling Interests (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Income from Non-Controlling Interests data on file, last reported at -$360279.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -360,279.69 |
| Jun 30, 2025 | -32.23 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Sep 30, 2024 | -5.93 Mn |
| Jun 30, 2024 | -8.83 Mn |
| Mar 31, 2024 | -8.67 Mn |
| Sep 30, 2023 | -8.44 Mn |
| Jun 30, 2023 | -6.80 Mn |
| Mar 31, 2023 | -9.59 Mn |
| Sep 30, 2022 | -5.28 Mn |
| Jun 30, 2022 | -4.85 Mn |
| Mar 31, 2022 | -11.26 Mn |
| Sep 30, 2021 | -11.07 Mn |
| Jun 30, 2021 | -12.70 Mn |
| Mar 31, 2021 | -13.46 Mn |
| Sep 30, 2020 | -10.85 Mn |
| Jun 30, 2020 | -7.52 Mn |
| Sep 30, 2019 | -4.77 Mn |
| Jun 30, 2019 | -6.90 Mn |
| Sep 30, 2018 | -3.28 Mn |